Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy

R A Moore, H J McQuay, J Tomaszewski, G Raba, D Tutunaru, N Lietuviete, J Galad, L Hagymasy, D Melka, J Kotarski, T Rechberger, B Fülesdi, A Nizzardo, C Guerrero-Bayón, S Cuadripani, B Pizà-Vallespir, M Bertolotti, R A Moore, H J McQuay, J Tomaszewski, G Raba, D Tutunaru, N Lietuviete, J Galad, L Hagymasy, D Melka, J Kotarski, T Rechberger, B Fülesdi, A Nizzardo, C Guerrero-Bayón, S Cuadripani, B Pizà-Vallespir, M Bertolotti

Abstract

Background: Dexketoprofen trometamol plus tramadol hydrochloride is a new oral combination of two analgesics, which have different mechanisms of action for the treatment of moderate to severe acute pain.

Methods: Randomised, double-blind, parallel, placebo and active-controlled, single and multiple-dose study to evaluate the analgesic efficacy and safety of dexketoprofen/tramadol 25 mg/75 mg in comparison with the single agents (dexketoprofen 25 mg and tramadol 100 mg) in moderate to severe acute pain after abdominal hysterectomy. Patients received seven consecutive doses of study drug within a 3-day period, each dose separated by an 8-hour interval. A placebo arm was included during the single-dose phase to validate the pain model. Efficacy assessments included pain intensity, pain relief, patient global evaluation and use of rescue medication. The primary endpoint was the mean sum of pain intensity differences over the first 8 h (SPID8).

Results: The efficacy analysis included 606 patients, with a mean age of 48 years (range 25-73). The study results confirmed the superiority of the combination over the single agents in terms of the primary endpoint (p <0.001). Secondary endpoints were generally supportive of the superiority of the combination for both single and multiple doses. Most common adverse drug reactions (ADRs) were nausea (4.6%) and vomiting (2.3%). All other ADRs were experienced by less than 2% of patients.

Conclusions: The study results provided robust evidence of the superiority of dexketoprofen/tramadol 25 mg/75 mg over the single components in the management of moderate to severe acute pain, as confirmed by the single-dose efficacy, repeated-dose sustained effect and good safety profile observed.

Trial registration: EU Clinical Trials Register (EudraCT number 2012-004545-32, registered 04 October 2012); Clinicaltrials.gov ( NCT01904149, registered 17 July 2013).

Figures

Fig. 1
Fig. 1
Study CONSORT flow diagram. Participant flow with the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome. Five patients in the ITT population received incorrect kit study treatment: *one patient was randomized to receive DKP (first dose placebo) but received DKP/TRAM (first dose placebo) instead; † one patient was randomized to receive DKP/TRAM (first dose active) but received TRAM (first dose active) instead; ‡ one patient was randomized to receive DKP (first dose active) but received TRAM (first dose placebo) instead; § one patient was randomized to receive TRAM (first dose placebo) but received DKP (first dose active) instead; ¶ one patient was randomized to receive TRAM (first dose active) but received DKP (first dose active) instead. ** Received at least one dose; alloc. allocated, ITT intention-to-treat, PP per protocol. The ITT population included all patients randomised; the safety population included all patients randomised who received at least one dose of study treatment; the PP population included all ITT patients with no major protocol violations; DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg; n: number of patients
Fig. 2
Fig. 2
Mean SPID over 8 h (single-dose phase) (Primary Endpoint). SPID summed pain intensity differences, DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg. Pain intensity (PI) was measured on a 0–100 visual analogue scale (VAS) with left end labelled “no pain” and right end labelled “worst possible pain”; * statistically significant versus both DKP and TRAM (p <0.001); † statistically significant versus placebo (p <0.05)
Fig. 3
Fig. 3
Time course of mean PI (VAS) scores at rest (single-dose phase). PI pain intensity, VAS visual analogue scale, DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg. PI was measured on a 0–100 VAS with left end labelled “no pain” and right end labelled “worst possible pain”; * statistically significant versus both DKP and TRAM (p <0.05); † statistically significant versus TRAM only (p <0.05); ‡ statistically significant versus placebo (p <0.05)
Fig. 4
Fig. 4
Time course of mean PI (VAS) scores at rest (multiple-dose phase). PI pain intensity, VAS visual analogue scale, DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg. PI was measured on a 0–100 VAS with left end labelled “no pain” and right end labelled “worst possible pain”; statistical significance was achieved versus DKP (p = 0.003) over the 48-hour multiple-dose period (mixed model for repeated measures approach)
Fig. 5
Fig. 5
Time course of mean PI (VAS) scores on movement (multiple-dose phase). PI pain intensity, VAS visual analogue scale, DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg. PI was measured on a 0–100 VAS with left end labelled “no pain” and right end labelled “worst possible pain”; pain on movement: elicited pain upon sitting; Statistical significance was achieved versus DKP (p <0.001) over the 48-hour multiple-dose period (mixed model for repeated measures approach)
Fig. 6
Fig. 6
Time course of mean SPID at rest (single-dose phase). SPID summed pain intensity differences, DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg. Pain intensity (PI) was measured on a 0–100 visual analogue scale (VAS) with left end labelled “no pain” and right end labelled “worst possible pain”; * statistically significant versus both DKP and TRAM (p <0.05); † statistically significant versus placebo (p <0.05)
Fig. 7
Fig. 7
Time course of mean PAR (VRS) scores (single-dose phase). PAR pain relief, VRS verbal rating scale, DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg. PAR was measured on a five-point VRS (0 = none, 1 = slight, 2 = moderate, 3 = good, 4 = complete) during the single-dose phase of the study; * statistically significant versus both DKP and TRAM (p <0.05); † statistically significant versus TRAM only (p <0.05); ‡ statistically significant versus placebo (p <0.05)

References

    1. Raffa RB, Tallarida RJ, Taylor R, Jr, Pergolizzi JV., Jr Fixed-dose combinations for emerging treatment of pain. Expert Opin Pharmacother. 2012;13(9):1261–70. doi: 10.1517/14656566.2012.668531.
    1. Moore RA, Derry CJ, Derry S, Straube S, McQuay HJ. A conservative method of testing whether combination analgesics produce additive or synergistic effects using evidence from acute pain and migraine. Eur J Pain. 2012;16(4):585–91. doi: 10.1016/j.ejpain.2011.08.009.
    1. McGurk M, Robinson P, Rajayogeswaran V, De Luca M, Casini A, Artigas R, et al. Clinical comparison of dexketoprofen trometamol, ketoprofen, and placebo in postoperative dental pain. J Clin Pharmacol. 1998;38(12 Suppl):46S–54S.
    1. Rodríguez MJ, Arbós RM, Amaro SR. Dexketoprofen trometamol: clinical evidence supporting its role as a painkiller. Expert Rev Neurother. 2008;8(11):1625–40. doi: 10.1586/14737175.8.11.1625.
    1. Moore RA, Derry S, Straube S, Ireson-Paine J, Wiffen PJ. Faster, higher, stronger? Evidence for formulation and efficacy for ibuprofen in acute pain. Pain. 2014;155(1):14–21. doi: 10.1016/j.pain.2013.08.013.
    1. Moore RA, Derry S, Straube S, Ireson-Paine J, Wiffen PJ. Validating speed of onset as a key component of good analgesic response in acute pain. Eur J Pain. 2015;19(2):187–92. doi: 10.1002/ejp.536.
    1. Barden J, Derry S, McQuay HJ, Moore RA. Single dose oral ketoprofen and dexketoprofen for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;4:CD007355.
    1. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879–923. doi: 10.2165/00003088-200443130-00004.
    1. Moore RA, Gay-Escoda C, Figueiredo R, Tóth-Bagi Z, Dietrich T, Milleri S, et al. Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain. J Headache Pain. 2015;16:60. doi: 10.1186/s10194-015-0541-5.
    1. Barden J, Edwards JE, Mc Quay HJ, Moore RA. Pain and analgesic response after third molar extraction and other postsurgical pain. Pain. 2004;107:86–90. doi: 10.1016/j.pain.2003.09.021.
    1. Jamison RN, Gracely RH, Raymond SA, Levine JG, Marino B, Herrmann TJ, et al. Comparative study of electronic vs. paper VAS rating: a randomized, crossover trial using healthy volunteers. Pain. 2002;99:341–7. doi: 10.1016/S0304-3959(02)00178-1.
    1. Collins SL, Edwards J, Moore RA, Smith LA, Mc Quay HJ. Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough? Pain. 2001;91:189–94. doi: 10.1016/S0304-3959(00)00435-8.
    1. Moore RA, Edwards JE, McQuay HJ. Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain. 2005;116(3):322–31. doi: 10.1016/j.pain.2005.05.001.
    1. Committee for Proprietary Medicinal Products (CPMP) Note for guidance on clinical investigation of medicinal products for treatment of nociceptive pain. London: CPMP/EWP/612/00; 2002.
    1. Singla N, Singla S, Minkowitz HS, Moodie J, Brown C. Intranasal ketorolac for acute postoperative pain. Curr Med Res Opin. 2010;26(8):1915–23. doi: 10.1185/03007995.2010.495564.
    1. Brandsborg B, Nikolajsen L, Kehlet H, Jensen TS. Chronic pain after hysterectomy. Acta Anaesthesiol Scand. 2008;52(3):327–31. doi: 10.1111/j.1399-6576.2007.01552.x.
    1. Aqua K, Gimbel JS, Singla N, Ma T, Ahdieh H, Kerwin R. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial. Clin Ther. 2007;29(6):1000–12. doi: 10.1016/j.clinthera.2007.06.001.
    1. Montes A, Warner W, Puig MM. Use of intravenous patient-controlled analgesia for the documentation of synergy between tramadol and metamizol. Br J Anaesth. 2000;85(2):217–23. doi: 10.1093/bja/85.2.217.
    1. Johnson GH, Van Wagoner JD, Brown J, Cooper SA. Bromfenac sodium, acetaminophen/oxycodone, ibuprofen, and placebo for relief of postoperative pain. Clin Ther. 1997;19(3):507–19. doi: 10.1016/S0149-2918(97)80135-X.
    1. Singla NK, Desjardins PJ, Chang PD. A comparison of the clinical and experimental characteristics of four acute surgical pain models: dental extraction, bunionectomy, joint replacement, and soft tissue surgery. Pain. 2014;155(3):441–56. doi: 10.1016/j.pain.2013.09.002.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir